Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Ocena Blokady Współczulnej Szyjno-Piersiowej w Przypadku Stanu po COVID-19 (CeASE)

5 października 2026 zaktualizowane przez: Anuj Bhatia, University Health Network, Toronto

A Randomized Controlled Trial for Cervicothoracic Sympathetic Chain Block Against Placebo Saline Injection Evaluation for Post COVID Condition: the CeASE RCT

Post-COVID Condition (PCC) affects roughly 2.1 million Canadians, carrying an annual economic burden of CAD $7.8-50.6 billion. It presents across multiple organ systems with symptoms including fatigue, brain fog, palpitations, and orthostatic intolerance, at an annual cost of CAD $1,675-$7,340 per case.

A key mechanism underlying many treatment-resistant PCC symptoms appears to be dysautonomia abnormal autonomic nervous system function driven by immune-mediated sympathetic overactivity. Persistent inflammation (cytokine storms, T/B-cell dysfunction, microclots) sustains sympathetic hyperactivity, which in turn perpetuates systemic inflammation and "sickness behaviors" resembling PCC symptoms.

Current treatments including beta blockers, ivabradine, fludrocortisone, and rehabilitation are limited by variable responses, side effects, and the complication of post-exertional symptom exacerbation. Emerging therapies (SSRIs, low-dose naltrexone, antihistamines, HBOT) show promise but lack robust trial evidence.

Cervicothoracic sympathetic chain block (CSB) a local anesthetic block of the cervical and upper thoracic sympathetic ganglia is a promising intervention that reduces sympathetic outflow, improves cerebral blood supply, and lowers pro-inflammatory cytokines. Small observational studies (16 studies, 224 patients) show benefit for PCC symptoms, but all lack placebo controls and have significant methodological heterogeneity.

The proposed study aims to fill this gap with a double-blind, placebo-controlled RCT to rigorously evaluate CSB's efficacy, magnitude of benefit, and durability in PCC patients.

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Szczegółowy opis

Post COVID Condition (PCC): In the wake of the COVID-19 pandemic, while many individuals recover fully from an acute COVID-19 infection, a substantial proportion experience ongoing or evolving symptoms well beyond the initial illness. These prolonged effects are broadly referred to as long COVID, also commonly referred to as the post-COVID conditions (PCC). The WHO defines long COVID as a condition following confirmed or probable SARS-CoV-2 infection, with symptoms lasting at least 2 months, typically beginning 3 months postinfection, and not explained by an alternative diagnosis. In Canada, at least 15 million people were infected with COVID-19 and 1 in 5 adults who had COVID-19 developed long-lasting symptoms after their initial infection. Of those, more than half (58.2% or about 2.1 million people) still have ongoing symptoms, defined as PCC. The annual economic burden of PCC in Canada is significant, with estimates from a Public Health Agency of Canada report suggesting a total healthcare cost between CAD 7.8 and CAD 50.6 billion. Costs per case can range from CAD 1,675 to CAD 7,340 in the first year after infection, with unvaccinated individuals experiencing higher costs and quality-adjusted life-year decrements.

Manifestations of and autonomic dysfunction in PCC: PCC presents in diverse ways and can affect multiple organ systems, including the cardiovascular, respiratory, neurological, and gastrointestinal systems. There is a range of symptoms that are encompassed within the syndrome of PCC, including fatigue, shortness of breath, chest pain, palpitations, headache, cognitive impairment ('brain fog'), rashes, anxiety, depression, gastrointestinal upset, persistent anosmia, and more with chronic fatigue and dyspnea as the most common. When cardiovascular or autonomic symptoms are present, clinicians are advised to evaluate for conditions associated with long-term sequelae of COVID-19 infection including myalgic encephalomyelitis or chronic fatigue syndrome; post-exertional malaise and post-exertional symptom exacerbation, dysautonomia with cardiac manifestations (e.g. inappropriate sinus tachycardia and postural orthostatic tachycardia syndrome (POTS: sustained and symptomatic increase in heart rate of ≥30 bpm within 10 minutes of standing without a drop in systolic BP ≥20 mmHg or diastolic BP ≥10 mmHg)), and mast cell activation syndrome (MCAS).

While some symptoms result from tissue damage of COVID-19, persistent symptoms despite tissue repair suggest additional mechanisms in PCC. A key hypothesis implicates pathological inflammation, potentially driven by persistent viral presence, T-cell dysfunction, and B-cell hyperactivity,sustaining a hyperinflammatory state. This process contributes to cytokine storms, immune dysregulation, multiorgan inflammation, reactivation of latent pathogens, autoimmunity, and microclot formation. The sympathetic nervous system plays a critical role in immune regulation. Sympathetic fibers innervate primary and secondary lymphoid organs, and immune cells express adrenergic receptors and neuropeptides, enabling modulation by neurotransmitters released from sympathetic nerve terminals. Through these mechanisms, the SNS regulates both immune homeostasis and pathological activation. This neuroimmune cross-talk provides context for understanding the role of SNS in chronic inflammation, including PCC. Symptoms resembling autonomic dysfunction have also been observed following various viral infections such as HIV and herpes viruses, and a similar pattern is evident in PCC. Symptoms such as brain fog, fatigue, chest pain, palpitations, and severe orthostatic intolerance syndromes suggest an interaction between inflammation and autonomic hyperactivity. These findings implicate the sympathetic nervous system as a potential therapeutic target for PCC.

Many PCC symptoms that are resistant to conventional treatments have been associated with dysautonomia an abnormal functioning of the autonomic nervous system, which regulates involuntary bodily functions such as heart rate and blood pressure, respiration, and digestion. While the underlying pathophysiology of PCC remains incompletely understood, emerging evidence suggests that the autonomic dysfunction in these patients reflect immune-mediated dysregulation of the autonomic nervous system. The sympathetic branch of the autonomic nervous system plays a key role in neuroimmune communication; however, this delicate balance can be disturbed by elevated levels of pro-inflammatory cytokines, which drive sympathetic overactivity and contribute to systemic inflammation. In SARS-CoV-2 infection, this process has been well described in the literature and attributed to the cytokine storm, in which sympathetic activation is a central component of the immune response. Heightened sympathetic signaling further engages the brainstem to initiate "sickness behaviors" a cluster of physiological and behavioral responses that closely resemble the symptomatology of PCC. When this state of sympathetic hyperactivity persists over time, it may contribute to, or exacerbate, the chronic and debilitating symptoms experienced by individuals with PCC.

Treatment approaches for PCC: Medications such as ivabradine, beta blockers, midodrine, and fludrocortisone are recommended by the Canadian POTS guidelines and may improve orthostatic tolerance and cerebral perfusion in POTS patients, including those with PCC. However, responses are highly variable, access remains a barrier, and side effects can be limiting. Rehabilitation is further complicated by post-exertional symptom exacerbation (PESE), which makes structured exercise risky for many PCC patients. Preliminary studies outside of PCC suggest possible benefit from transcutaneous vagus nerve stimulation and jugular vein compression collars, but do not achieve symptom remission and benefits may wane once the user stops wearing the device.

Current treatment approaches include very few interventions backed by clinical trials, emerging therapies from patient-led research, and off-label or self-directed treatments. There is growing evidence for symptom-based pharmacologic treatments for specific PCC phenotypes including hyperbaric oxygen therapy (HBOT). Antihistamines have shown benefit in patients with MCAS features, improving symptoms in small studies. Other off-label therapies with emerging support include SSRIs, which may reduce neuroinflammation and brain fog by modulating serotonin and cytokine pathways; Maraviroc, a CCR5 antagonist that may disrupt the monocytic-endothelial-platelet axis in inflammatory states; and low-dose naltrexone, which may restore function in natural killer cells to reduce post-COVID fatigue and pain.

Role of cervicothoracic sympathetic chain block for PCC: The cervicothoracic sympathetic chain includes the superior, middle, intermediate, inferior cervical and the upper thoracic sympathetic ganglia. The inferior cervical sympathetic and the first thoracic sympathetic ganglia combine to form the stellate ganglion on each side and these ganglia are located at the level of the first rib, posterolateral to the longus colli muscle. The right stellate ganglion innervates the sinoatrial node and the right ventricle and its stimulation results in chronotropy, increased contractility, and arrhythmias. Its post ganglionic fibers also innervate the right side of the face, the right upper limb and the right lung and bronchi. The left stellate ganglion innervates the atrioventricular node and the left ventricle and its stimulation results in chronotropy, increased contractility, and arrhythmias. Its post ganglionic fibers also innervate the left side of the face, the left upper limb and the left lung and bronchi.

The cervicothoracic sympathetic chain block (CSB) is a local anesthetic block of the middle and lower cervical and upper thoracic sympathetic trunk. We have demonstrated that an ultrasound-guided injection of 5 cc of LA in the sympathetic chain at the level of the sixth cervical transverse process spreads from the fourth cervical to the first thoracic levels and blocks middle and lower cervical and upper thoracic sympathetic ganglia. We have also evaluated variations in relevant sonoanatomy for anterior and lateral approaches for CSB in a large cohort. More recently, we and others have synthesized the evidence for the role of CSBs in non-pain indications with autonomic hyperfunction including arrhythmias, peripheral vascular disease, anxiety, and other medical conditions associated with autonomic dysfunction. The effectiveness of CSB for these conditions stems from the intervention's ability to block sympathetically mediated disease manifestations. These blocks manifest their therapeutic effects through three main mechanisms: 1) blocking neural connections in the region of innervation (cervical sympathetic trunk); 2) improving blood supply to organs including the brain; and 3) reducing the plasma concentration of stress hormones and pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α,) and downregulation of NF- κB signaling. There is also evidence for persistence of therapeutic benefit from multiple consecutive CSB from a few weeks to one year despite the local anesthetics having a half-life of a few hours.

The left stellate ganglion has a greater influence on heart rate and contractility as compared to the right. Left-sided CSB have shown benefit in alleviating symptoms of PCC in cohort studies by obtunding the activity of the sympathetic nervous system outflow. A recent scoping review reported results of CSB in 16 small observational studies on 224 patients with PCC with preliminary evidence for alleviating symptoms of autonomic dysfunction in patients with PCC. However, all these studies lacked placebo or sham intervention-controlled comparators, and the reported outcomes were subjective. Further, there was considerable heterogeneity in the approach to achieving CSB in terms of laterality, injectate composition and volume, and frequency of procedures. Given the subjective nature of PCC, it is crucial to distinguish between the therapeutic benefit and the placebo effects of this intervention while also establishing the magnitude and longevity of this benefit.

To address this gap, our research group is uniquely positioned to evaluate the efficacy of CSB in a double-blind, randomized controlled trial, establishing more rigorous evidence for its potential role in the treatment of PCC.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

78

Faza

  • Faza 4

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • Ontario
      • Toronto, Ontario, Kanada, M5T 2S8
        • Rekrutacyjny
        • Toronto Western Hospital
        • Kontakt:
        • Kontakt:
      • Toronto, Ontario, Kanada, M5S 1B3
        • Jeszcze nie rekrutacja
        • Women's College Hospital
        • Kontakt:
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion criteria

  1. Age 18 years or older
  2. PCC following COVID-19 infection with symptoms lasting for at least three months
  3. Ability to read, write, and understand English
  4. Quantified autonomic symptoms from at least one domain as reported by the patient on the screener Composite Autonomic Symptom Score (COMPASS-31), i.e. a COMPASS-31 score greater than 0. COMPASS-31 assesses 6 domains of autonomic symptoms: Orthostatic Intolerance, Vasomotor, Secretomotor, Gastrointestinal, Bladder, and Pupillomotor.
  5. Patients should be stable on any PCC-related medications for at least four weeks.

Exclusion criteria

  1. History of co-existing conditions that are a contraindication for CSB:

    1. Unilateral vocal cord paralysis; Severe chronic obstructive pulmonary disease (FEV1 between 30-50% of predicted value)
    2. Recent myocardial infarction (within the last one year), Cardiac conduction block of any degree
    3. Glaucoma
    4. Infection or mass at injection site, bleeding disorders
  2. Comorbid conditions that could confound study results, such as:

    1. Active autoimmune disorders
    2. Pre-existing autonomic dysfunction (e.g. POTS, IST, and CRPS) prior to COVID-19
    3. Untreated psychiatric conditions (e.g. severe anxiety or PTSD requiring medication adjustments during the study period)
  3. Recent history of major surgery or cerebrovascular events within the last three months

  4. Allergy to local anesthetic; Inability to extend the neck for any reason (e.g. severe arthritis)

  5. History of prior stellate ganglion block

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Poczwórny

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Active group

The active group will have cervical sympathetic block (CSB) on both the left and right sides using up to 5 mL of 0.25% bupivacaine with epinephrine (1:200,000).

The active group will have cervical sympathetic block (CSB) on both the left and right sides using up to 5 mL of 0.25% bupivacaine with epinephrine (1:200,000). After the injection, all patients will be monitored for a minimum of 30 minutes to check for expected effects of the block and to watch for any side effects or complications.

Inne nazwy:
  • Aktywna grupa
Komparator placebo: Placebo (Saline) Control

Participants will receive cervicothoracic sympathetic chain block (CSB) on both the left and right sides using up to 5 mL of normal saline (0.9% NaCl), by an identical ultrasound-guided approach to the active arm. After the injection, all participants will be monitored for a minimum of 30 minutes for expected effects of the block and for side effects or complications.

Participants will receive cervicothoracic sympathetic chain block (CSB) on both the left and right sides using up to 5 mL of normal saline (0.9% NaCl), by an identical ultrasound-guided approach to the active arm. After the injection, all participants will be monitored for a minimum of 30 minutes for expected effects of the block and for side effects or complications.

Inne nazwy:
  • 5 ml soli fizjologicznej (0,9% NaCl)

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change from baseline in the Modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) Symptom Severity subscale score
Ramy czasowe: One month after the final injection.

Description: The C19-YRSm Symptom Severity subscale is scored from 0 to 30, with higher scores indicating greater symptom burden. The outcome is the change from baseline in this score.

One month after the final injection.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
C19-YRSm Symptom Severity subscale score
Ramy czasowe: Three months after the final injection.

The C19-YRSm Symptom Severity subscale is scored from 0 to 30, with higher scores indicating greater symptom burden. The outcome is the change from baseline in this score.

Three months after the final injection.
Autonomic symptom burden (COMPASS-31)
Ramy czasowe: collected at screening, one month and three months after the final injection.

Weighted total score and the six domain scores (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, pupillomotor).

collected at screening, one month and three months after the final injection.
Heart rate variability
Ramy czasowe: collected at screening, one month and three months after the final injection.

Heart rate variability over a five-minute recording.

collected at screening, one month and three months after the final injection.
Heart rate and blood pressure responses to autonomic challenge
Ramy czasowe: collected at screening, one month and three months after the final injection.

Valsalva manoeuvre, deep breathing, hyperventilation, and postural change (lying to sitting; sitting to standing).

collected at screening, one month and three months after the final injection.
One-minute sit-to-stand test.
Ramy czasowe: collected at screening, one month and three months after the final injection.

sitting to standing heart rate and blood pressure responses to autonomic challenge

collected at screening, one month and three months after the final injection.
Serum pro-inflammatory cytokines
Ramy czasowe: collected at screening, one month and three months after the final injection.

Measurement of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-α).

collected at screening, one month and three months after the final injection.
Generalized Anxiety Disorder-7 (GAD-7)
Ramy czasowe: collected at screening, one month and three months after the final injection.

The GAD-7 is a 7-item self-report questionnaire designed to screen for and measure the severity of generalized anxiety symptoms over the previous two weeks. Patients rate how often they have been bothered by symptoms such as excessive worry, nervousness, irritability, and difficulty relaxing. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity.

collected at screening, one month and three months after the final injection.
Patient Health Questionnaire-9 (PHQ-9)
Ramy czasowe: collected at screening, one month and three months after the final injection.

The PHQ-9 is a 9-item self-administered questionnaire used to screen for and assess the severity of depressive symptoms over the preceding two weeks. It evaluates symptoms including depressed mood, loss of interest or pleasure, sleep disturbances, fatigue, appetite changes, concentration difficulties, feelings of worthlessness, psychomotor changes, and suicidal ideation. Scores range from 0 to 27, with higher scores reflecting more severe depression.

collected at screening, one month and three months after the final injection.
Hospital Anxiety and Depression Scale (HADS)
Ramy czasowe: collected at screening, one month and three months after the final injection.

The HADS is a 14-item self-report instrument developed to assess anxiety and depression in medical and outpatient settings while minimizing the influence of physical symptoms related to medical illness. It consists of two subscales: HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D), each containing 7 items. Scores for each subscale range from 0 to 21, with higher scores indicating greater symptom severity.

collected at screening, one month and three months after the final injection.
EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
Ramy czasowe: collected at screening, one month and three months after the final injection.

The EQ-5D-5L is a standardized, preference-based measure of health-related quality of life developed by the EuroQol Group. It assesses health status across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels ranging from no problems to extreme problems/unable to perform activities. The questionnaire also includes a visual analogue scale (EQ VAS), on which participants rate their overall health from 0 ("the worst health you can imagine") to 100 ("the best health you can imagine"). Higher index and VAS scores indicate better perceived health-related quality of life.

collected at screening, one month and three months after the final injection.
Sleep Quality
Ramy czasowe: collected at screening, one month and three months after the final injection.

Pittsburgh Sleep Quality Index (PSQI)

The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire designed to assess subjective sleep quality and sleep disturbances over the previous month. The instrument comprises 19 items that generate seven component scores evaluating subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. These component scores are summed to produce a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality. A global score greater than 5 is commonly used to identify clinically significant sleep disturbances.

collected at screening, one month and three months after the final injection.
Actigraphy-measured sleep-Monitoring sleep
Ramy czasowe: collected at screening, one month and three months after the final injection.

Monitoring sleep onset latency, total sleep time, number of awakenings.

collected at screening, one month and three months after the final injection.
Actigraphy-measured sleep-Monitoring daytime activities
Ramy czasowe: collected at screening, one month and three months after the final injection.

Time spent in sedentary, mild, moderate and vigorous activity.

collected at screening, one month and three months after the final injection.

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Incidence of adverse events and serious adverse events.
Ramy czasowe: from the first injection to the three-month assessment

Events will be reported by arm, with needle-related events tabulated separately from drug-related and sympatholysis-related events.

from the first injection to the three-month assessment
Proportion of participants with a reduction of ≥4 points on the C19-YRSm Symptom Severity subscale
Ramy czasowe: one month after the final injection

The threshold is taken from the reported MCID and is not a validated responder definition

one month after the final injection
Difference in treatment effect between participants with and without postural orthostatic tachycardia syndrome (POTS), not powered for interaction; hypothesis-generating.
Ramy czasowe: one month after the final injection

Difference in treatment effect between participants with and without postural orthostatic tachycardia syndrome (POTS) not powered for interaction; hypothesis-generating.

one month after the final injection
Difference in treatment effect by baseline autonomic symptom burden
Ramy czasowe: one month after the final injection

COMPASS-31 weighted total above versus below the cohort median; not powered for interaction.

one month after the final injection
Assessment of blinding success
Ramy czasowe: Three months after the final injection

Participant and outcome assessor treatment-allocation guesses collected at the 3-month follow-up to evaluate maintenance of blinding.

Three months after the final injection

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Anuj Bhatia, MD, PhD, University Health Network, Toronto

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

19 maja 2026

Zakończenie podstawowe (Szacowany)

20 maja 2027

Ukończenie studiów (Szacowany)

1 września 2027

Daty rejestracji na studia

Pierwszy przesłany

26 lutego 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 marca 2026

Pierwszy wysłany (Rzeczywisty)

12 marca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

9 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

5 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 5627

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data underlying the published results will be made available to investigators whose proposed use of the data has been approved by the trial steering committee

Ramy czasowe udostępniania IPD

Beginning nine months after publication of the primary results and ending five years thereafter.

Kryteria dostępu do udostępniania IPD

Requests should be directed to the corresponding author. Requesters must submit a methodologically sound proposal and sign a data sharing agreement.

Typ informacji pomocniczych dotyczących udostępniania IPD

  • PROTOKÓŁ BADANIA
  • SOK ROŚLINNY
  • ICF

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .